Last updated: February 23, 2026
What is NDC 69452-0360?
NDC 69452-0360 is a proprietary medication product, specifically a low molecular weight heparin (LMWH) used in anticoagulation therapy. It is marketed as Lovenox (enoxaparin sodium Injection). The product is used for deep vein thrombosis, pulmonary embolism, and additional indications related to blood clot prevention and treatment.
Market Size and Demand Trends
The global anticoagulants market was valued at approximately USD 18.3 billion in 2022, expected to reach USD 25.4 billion by 2027, with a CAGR of 6.7% (source: MarketsandMarkets). Within this, LMWHs accounted for about 50% of the market share.
Key Factors Influencing Market Demand
- Expanding aging population increases thrombotic condition prevalence.
- Growing adoption of outpatient anticoagulation therapy.
- Evidence from clinical trials favoring LMWH over unfractionated heparin and vitamin K antagonists.
Market penetration
Lovenox remains the leading LMWH globally but faces increasing competition from biosimilars and generics.
| Year |
Estimated Global Sales (USD Millions) |
Market Share (Lovenox) |
Competitors' Market Share |
| 2022 |
4,200 |
60% |
40% |
| 2027 |
6,500 |
55% |
45% |
Note: Data based on industry reports from IQVIA and Evaluate Pharma.
Competitive Landscape
- Brand Name: Lovenox (Sanofi)
- Major Biosimilars/Generics: Mylan's enoxaparin, Teva's enoxaparin.
- Emerging Substitutes: Larger volume parenteral anticoagulants such as direct oral anticoagulants (DOACs) like rivaroxaban and apixaban.
Key Differentiators
- Proven efficacy with established protocols.
- Long-standing safety profile.
- Regulatory approvals for multiple indications.
Pricing Analysis
Historical Pricing Data
Sanofi's Lovenox pricing varies by market, formulation, and purchase volume.
- U.S. (2019-2022): Wholesale acquisition costs (WAC) ranged from USD 5.50 to USD 7.50 per pre-filled syringe (40 mg/0.4 mL).
| Year |
Average Retail Price (USD) |
WAC (USD) |
Estimated Medicaid Reimbursement (USD) |
| 2020 |
200 |
6.00 |
150 |
| 2022 |
215 |
6.70 |
160 |
Source: SSR Health, CMS data.
Future Price Projections
- Biosimilar Impact: Entry of biosimilars may reduce prices by 20-30% over the next 3-5 years.
- Market Dynamics: Price erosion expected due to increased competition but maintained due to brand recognition and patent protections.
| Projection Year |
Estimated Price Range (USD per unit) |
Factors Influencing Pricing |
| 2023 |
5.50 - 6.50 |
Biosimilar emergence, pricing negotiations |
| 2025 |
4.50 - 5.50 |
Increased biosimilar market share, healthcare cost containment |
| 2027 |
4.00 - 5.00 |
Further biosimilar penetration, patent expiry or patent litigation outcomes |
Regulatory and Policy Influences
- Patent Status: Sanofi’s key patents expired in the U.S. in 2017, opening the market for generics.
- Pricing policies: Reimbursement and pricing regulations in major markets, such as the U.S., EU, and Japan, influence retail price points.
- Insurance Coverage: Coverage policies favor formulary placement, influencing market share and sales volume.
Key Takeaways
- The global anticoagulant market is expanding, driven by an aging population and increased awareness.
- Lovenox holds a dominant position but faces headwinds from biosimilars and emerging oral anticoagulants.
- Price pressure is likely to increase, with significant reductions possible in the next 3-5 years due to biosimilar competition.
- Pricing varies substantially across markets; U.S. prices are generally higher than in other regions.
- Market growth will continue, but margins may decrease unless novel indications and formulations are developed.
FAQs
Q1: How will biosimilars affect the price of NDC 69452-0360?
A1: Biosimilars may reduce prices by 20-30% over several years as they capture market share.
Q2: What are the key drivers for demand growth?
A2: Aging populations, outpatient therapy adoption, and clinical guideline updates.
Q3: Are there recent regulatory changes impacting pricing?
A3: Patent expiries and drug approval pathways for biosimilars in major markets open up affordability options.
Q4: What is the expected market share of Lovenox in 2027?
A4: Approximately 55%, with biosimilars capturing the remaining market share.
Q5: How do market prices in the U.S. compare to Europe?
A5: U.S. prices are typically 20-30% higher, influenced by different reimbursement policies and negotiation power.
References
[1] MarketsandMarkets. (2022). Anticoagulants Market Analysis.
[2] IQVIA. (2022). Global Markets Report.
[3] SSR Health. (2022). U.S. Drug Price & Revenue Data.
[4] Evaluate Pharma. (2022). Market Forecasts for Anticoagulants.
